Clinical Trial Update: Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating radiotherapy with carboplatin/paclitaxel and nivolumab for high-risk HPV-related oropharyngeal squamous cell carcinoma has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Oropharynx Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-01-22